Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kurt Dejgaard

Low Free Drug Concentration Prevents Inhibition of F508del CFTR Functional Expression by the Potentiator VX-770 (Ivacaftor)

British Journal of Pharmacology

Pharmacology

2016

English

Related publications

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-Dependent but ATP-independent Manner

Journal of Biological Chemistry

English

VX-770-mediated Potentiation of Numerous Human CFTR Disease Mutants Is Influenced by Phosphorylation Level

Scientific Reports

Multidisciplinary

2019

English

Functional Rescue of F508del-CFTR Using Small Molecule Correctors

Frontiers in Pharmacology

Pharmacology

2012

English

Combination Potentiator (‘Co-Potentiator’) Therapy for CF Caused by CFTR Mutants, Including N1303K, That Are Poorly Responsive to Single Potentiators

Journal of Cystic Fibrosis

English

A Kinase-Directed Approach to Rescue Functionality of F508del CFTR

Postdoc Journal

2016

English

Prs16 - Modeled Survival Gains of Patients With Cystic Fibrosis (Cf) Aged ≥12 Years Heterozygous for F508del-CFTR and a Residual Function Mutation (F508del/Rf) Treated With the Cf Transmembrane Conductance Regulator Modulator (Cftrm) Tezacaftor/Ivacaftor (Tez/Iva)

English

Biophysical Characterisation of Calumenin as a Charged F508del-CFTR Folding Modulator

PLoS ONE

Multidisciplinary

2014

English

Cysteamine Re-Establishes the Clearance of Pseudomonas Aeruginosa by Macrophages Bearing the Cystic Fibrosis-Relevant F508del-CFTR Mutation

Cell Death and Disease

Molecular Neuroscience

English

Functional Inhibition of Chemokine Receptor CCR2 by Dicer-Substrate-siRNA Prevents Pain Development

Molecular Neuroscience

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kurt Dejgaard

Low Free Drug Concentration Prevents Inhibition of F508del CFTR Functional Expression by the Potentiator VX-770 (Ivacaftor)

Related publications

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-Dependent but ATP-independent Manner

VX-770-mediated Potentiation of Numerous Human CFTR Disease Mutants Is Influenced by Phosphorylation Level

Functional Rescue of F508del-CFTR Using Small Molecule Correctors

Combination Potentiator (‘Co-Potentiator’) Therapy for CF Caused by CFTR Mutants, Including N1303K, That Are Poorly Responsive to Single Potentiators

A Kinase-Directed Approach to Rescue Functionality of F508del CFTR

Prs16 - Modeled Survival Gains of Patients With Cystic Fibrosis (Cf) Aged ≥12 Years Heterozygous for F508del-CFTR and a Residual Function Mutation (F508del/Rf) Treated With the Cf Transmembrane Conductance Regulator Modulator (Cftrm) Tezacaftor/Ivacaftor (Tez/Iva)

Biophysical Characterisation of Calumenin as a Charged F508del-CFTR Folding Modulator

Cysteamine Re-Establishes the Clearance of Pseudomonas Aeruginosa by Macrophages Bearing the Cystic Fibrosis-Relevant F508del-CFTR Mutation

Functional Inhibition of Chemokine Receptor CCR2 by Dicer-Substrate-siRNA Prevents Pain Development